Therefore, reorganizing Luminal B (HER2‐negative) BC by measuring the expression of PR and Ki67 instead of gene expression has clinical significance for accurately assessing the prognosis of BC and providing a reliable basis for clinical treatment. Here, ERBB2 is linked to breast cancer.